25-nitro-20-epi-vitamin D analogue with anti-proliferative and cytoprotective properties: Biological and pharmacological evaluation

We report the synthesis and pharmacological evaluation of UG-635, a novel 25-nitro vitamin D analogue bearing a 20-epimeric configuration. Cytotoxicity studies in SH-SY5Y neuroblastoma and HepG2 hepatocarcinoma cells showed that UG-635 is well tolerated at low concentrations but reduces viability at higher doses. Importantly, UG-635 demonstrated protective effects against oxidative stress in neuronal cells and exhibited anti-proliferative activity in breast cancer (MCF7) and osteoblast (MC3T3-E1) models, with efficacy comparable to calcitriol. Structural and crystallographic analyses revealed efficient binding to the vitamin D receptor (VDR), stabilizing its active conformation through favorable interactions with anchoring histidines. These findings highlight UG-635 as a promising vitamin D analogue with potential pharmacological relevance in cancer and neurodegenerative disease contexts, combining anti-proliferative and cytoprotective properties.

Authors

Institutions

Publication Details

Journal
Experimental and Molecular Pathology
Published
2026-02-23
DOI
https://doi.org/10.1016/j.yexmp.2026.105036
Primary Topic
Vitamin D Research Studies
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

25-nitro-20-epi-vitamin D analogue with anti-proliferative and cytoprotective properties: Biological and pharmacological evaluation

Carlos A. H. Fernandes, Annemieke Verstuyf, Natacha Rochel, Uxía Gómez-Bouzó et al.
Experimental and Molecular Pathology
Vitamin D Research Studies
article

25-nitro-20-epi-vitamin D analogue with anti-proliferative and cytoprotective properties: Biological and pharmacological evaluation

Carlos A. H. Fernandes, Annemieke Verstuyf, Natacha Rochel, Uxía Gómez-Bouzó, Lieve Verlinden, Fall Yagamare, Carole Peluso-Iltis, Generosa Gómez, Sandra Barreiro, Fernanda Borges
article en

Abstract

We report the synthesis and pharmacological evaluation of UG-635, a novel 25-nitro vitamin D analogue bearing a 20-epimeric configuration. Cytotoxicity studies in SH-SY5Y neuroblastoma and HepG2 hepatocarcinoma cells showed that UG-635 is well tolerated at low concentrations but reduces viability at higher doses. Importantly, UG-635 demonstrated protective effects against oxidative stress in neuronal cells and exhibited anti-proliferative activity in breast cancer (MCF7) and osteoblast (MC3T3-E1) models, with efficacy comparable to calcitriol. Structural and crystallographic analyses revealed efficient binding to the vitamin D receptor (VDR), stabilizing its active conformation through favorable interactions with anchoring histidines. These findings highlight UG-635 as a promising vitamin D analogue with potential pharmacological relevance in cancer and neurodegenerative disease contexts, combining anti-proliferative and cytoprotective properties.

Experimental and Molecular PathologyVol. 145
Centre National de la Recherche Scientifique (FR), Inserm (FR), Universidade do Porto (PT), Institut de génétique et de biologie moléculaire et cellulaire (FR), Rede de Química e Tecnologia (PT), Universidade de Vigo (ES), Université de Strasbourg (FR), KU Leuven (BE)
Agence Nationale de la Recherche, Fonds Wetenschappelijk Onderzoek, Universidade de Vigo, Xunta de Galicia, French Infrastructure for Integrated Structural Biology, Vlaamse regering, Fundação para a Ciência e a Tecnologia
Zero hunger
Openalex Percentile: Top 47%
Vitamin D Research Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.